88. Chronic thromboembolic pulmonary hypertension
145 clinical trials,   112 drugs   (DrugBank: 22 drugs),   13 drug target genes,   52 drug target pathways

Searched query = "Chronic thromboembolic pulmonary hypertension", "CTEPH", "Idiopathic chronic pulmonary thromboembolism"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
13 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2012-001642-17-IT
(EUCTR)
06/08/201412/09/2013An extension study of a drug to treat Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)An open-label extension study of the long-term safety, tolerability and efficacy of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) Subjects with inoperable Chronic Thromboembolic PulmonaryHypertension (CTEPH)
MedDRA version: 17.0;Level: LLT;Classification code 10068739;Term: Chronic thromboembolic pulmonary hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Trade Name: Volibris
Product Name: Ambrisentan
Product Code: GSK1325760
INN or Proposed INN: AMBRISENTAN
Other descriptive name: Ambrisentan
GlaxoSmithKline Research & Developement LtdNULLNot RecruitingFemale: yes
Male: yes
160Phase 3United States;Spain;Korea, Democratic People's Republic of;Turkey;Austria;Israel;Russian Federation;United Kingdom;Italy;Czech Republic;Mexico;Canada;Argentina;Brazil;Netherlands;Germany;China;Japan
2EUCTR2012-001646-18-IT
(EUCTR)
08/04/201426/06/2013Study of a drug to treat chronic thromboembolic pulmonary hypertension (CTEPH)A randomised, multicentre, double-blind, placebo-controlled studyof ambrisentan in subjects with inoperable chronic thromboembolicpulmonary hypertension (CTEPH) subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
MedDRA version: 16.0;Level: LLT;Classification code 10068739;Term: Chronic thromboembolic pulmonary hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Trade Name: Volibris
Product Name: GSK1325760
Product Code: GSK1325760
INN or Proposed INN: Ambrisentan
Other descriptive name: ambrisentan
GlaxoSmithKline Research & Developement LtdNULLNot RecruitingFemale: yes
Male: yes
160Phase 3Spain;Austria;Russian Federation;Italy;United Kingdom;France;Czech Republic;Mexico;Canada;Argentina;Brazil;Netherlands;Germany;China;Japan;Korea, Republic of
3EUCTR2012-001642-17-NL
(EUCTR)
16/12/201315/08/2013An extension study of a drug to treat Chronic Thromboembolic Pulmonary Hypertension (CTEPH)An open-label extension study of the long-term safety, tolerability and efficacy of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
MedDRA version: 16.0;Level: LLT;Classification code 10068739;Term: Chronic thromboembolic pulmonary hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Trade Name: Volibris
Product Name: GSK1325760
Product Code: GSK1325760
INN or Proposed INN: AMBRISENTAN
Other descriptive name: ambrisentan
GlaxoSmithKline Research & Developement LtdNULLNot RecruitingFemale: yes
Male: yes
160Spain;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Mexico;Canada;Argentina;Brazil;Netherlands;Germany;Japan;China;Korea, Republic of
4EUCTR2012-001646-18-NL
(EUCTR)
27/09/201315/08/2013Study of a drug to treat chronic thromboembolic pulmonary hypertension (CTEPH)A randomised, multicentre, double-blind, placebo-controlled studyof ambrisentan in subjects with inoperable chronic thromboembolicpulmonary hypertension (CTEPH) subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
MedDRA version: 17.0;Level: LLT;Classification code 10068739;Term: Chronic thromboembolic pulmonary hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Trade Name: Volibris
Product Name: GSK1325760
Product Code: GSK1325760
INN or Proposed INN: Ambrisentan
Other descriptive name: ambrisentan
GlaxoSmithKline Research & Developement LtdNULLNot RecruitingFemale: yes
Male: yes
160Spain;Turkey;Austria;Russian Federation;Israel;Italy;United Kingdom;France;Czech Republic;Mexico;Canada;Argentina;Brazil;Netherlands;Germany;Japan;China;Korea, Republic of
5EUCTR2012-001642-17-CZ
(EUCTR)
18/09/201301/08/2013An extension study of a drug to treat Chronic Thromboembolic Pulmonary Hypertension (CTEPH)An open-label extension study of the long-term safety, tolerability and efficacy of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
MedDRA version: 14.1;Level: LLT;Classification code 10068739;Term: Chronic thromboembolic pulmonary hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Trade Name: Volibris
Product Name: GSK1325760
Product Code: GSK1325760
INN or Proposed INN: AMBRISENTAN
Other descriptive name: ambrisentan
GlaxoSmithKline Research & Developement LtdNULLNot RecruitingFemale: yes
Male: yes
160Phase 3Spain;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Mexico;Canada;Argentina;Brazil;Netherlands;Germany;China;Japan;Korea, Republic of
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2012-001646-18-CZ
(EUCTR)
18/09/201309/07/2013Study of a drug to treat chronic thromboembolic pulmonary hypertension (CTEPH)A randomised, multicentre, double-blind, placebo-controlled studyof ambrisentan in subjects with inoperable chronic thromboembolicpulmonary hypertension (CTEPH) subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
MedDRA version: 17.0;Level: LLT;Classification code 10068739;Term: Chronic thromboembolic pulmonary hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Trade Name: Volibris
Product Name: GSK1325760
Product Code: GSK1325760
INN or Proposed INN: Ambrisentan
Other descriptive name: ambrisentan
GlaxoSmithKline Research & Developement LtdNULLNot RecruitingFemale: yes
Male: yes
160Spain;Turkey;Austria;Russian Federation;Israel;United Kingdom;Italy;Czech Republic;Mexico;Canada;Argentina;Brazil;Netherlands;Germany;China;Japan;Korea, Republic of
7EUCTR2012-001646-18-GB
(EUCTR)
02/09/201312/06/2013Study of a drug to treat chronic thromboembolic pulmonary hypertension (CTEPH)A randomised, multicentre, double-blind, placebo-controlled studyof ambrisentan in subjects with inoperable chronic thromboembolicpulmonary hypertension (CTEPH) subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
MedDRA version: 17.0;Level: LLT;Classification code 10068739;Term: Chronic thromboembolic pulmonary hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Trade Name: Volibris
Product Name: GSK1325760
Product Code: GSK1325760
INN or Proposed INN: Ambrisentan
Other descriptive name: ambrisentan
GlaxoSmithKline Research & Developement LtdNULLNot RecruitingFemale: yes
Male: yes
160Spain;Turkey;Austria;Russian Federation;Israel;United Kingdom;Italy;Czech Republic;Mexico;Canada;Argentina;Brazil;Netherlands;Germany;China;Japan;Korea, Republic of
8EUCTR2012-001646-18-DE
(EUCTR)
30/07/201305/06/2013Study of a drug to treat chronic thromboembolic pulmonary hypertension (CTEPH)A randomised, multicentre, double-blind, placebo-controlled studyof ambrisentan in subjects with inoperable chronic thromboembolicpulmonary hypertension (CTEPH) subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
MedDRA version: 17.0;Level: LLT;Classification code 10068739;Term: Chronic thromboembolic pulmonary hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Trade Name: Volibris
Product Name: GSK1325760
Product Code: GSK1325760
INN or Proposed INN: Ambrisentan
Other descriptive name: ambrisentan
GlaxoSmithKline Research & Developement LtdNULLNot RecruitingFemale: yes
Male: yes
160Spain;Turkey;Austria;Russian Federation;Israel;United Kingdom;Italy;Czech Republic;Mexico;Canada;Argentina;Brazil;Netherlands;Germany;China;Japan;Korea, Republic of
9EUCTR2012-001642-17-DE
(EUCTR)
30/07/201305/06/2013An extension study of a drug to treat Chronic Thromboembolic Pulmonary Hypertension (CTEPH)An open-label extension study of the long-term safety, tolerability and efficacy of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
MedDRA version: 17.1;Level: LLT;Classification code 10068739;Term: Chronic thromboembolic pulmonary hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Trade Name: Volibris
Product Name: GSK1325760
Product Code: GSK1325760
INN or Proposed INN: AMBRISENTAN
Other descriptive name: ambrisentan
GlaxoSmithKline Research & Developement LtdNULLNot RecruitingFemale: yes
Male: yes
160United States;Saudi Arabia;Spain;Turkey;Austria;Russian Federation;United Kingdom;Italy;Czech Republic;Mexico;Canada;Argentina;Brazil;Netherlands;Germany;China;Japan
10EUCTR2012-001642-17-AT
(EUCTR)
19/07/201304/06/2013An extension study of a drug to treat Chronic Thromboembolic Pulmonary Hypertension (CTEPH)An open-label extension study of the long-term safety, tolerability and efficacy of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
MedDRA version: 14.1;Level: LLT;Classification code 10068739;Term: Chronic thromboembolic pulmonary hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Trade Name: Volibris
Product Name: GSK1325760
Product Code: GSK1325760
INN or Proposed INN: AMBRISENTAN
Other descriptive name: ambrisentan
GlaxoSmithKline Research & Developement LtdNULLNot RecruitingFemale: yes
Male: yes
160Spain;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Mexico;Canada;Argentina;Brazil;Germany;Netherlands;China;Japan;Korea, Republic of
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2012-001646-18-AT
(EUCTR)
11/07/201304/06/2013Study of a drug to treat chronic thromboembolic pulmonary hypertension (CTEPH)A randomised, multicentre, double-blind, placebo-controlled studyof ambrisentan in subjects with inoperable chronic thromboembolicpulmonary hypertension (CTEPH) subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
MedDRA version: 14.1;Level: LLT;Classification code 10068739;Term: Chronic thromboembolic pulmonary hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Trade Name: Volibris
Product Name: GSK1325760
Product Code: GSK1325760
INN or Proposed INN: Ambrisentan
Other descriptive name: ambrisentan
GlaxoSmithKline Research & Developement LtdNULLNot RecruitingFemale: yes
Male: yes
160Spain;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Mexico;Canada;Argentina;Brazil;Netherlands;Germany;China;Japan;Korea, Republic of
12EUCTR2012-001642-17-ES
(EUCTR)
26/04/201306/03/2013An extension study of a drug to treat Chronic Thromboembolic Pulmonary Hypertension (CTEPH)An open-label extension study of the long-term safety, tolerability and efficacy of ambrisentan in subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) Subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH).
MedDRA version: 15.1;Level: LLT;Classification code 10068739;Term: Chronic thromboembolic pulmonary hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Trade Name: Volibris
Product Name: GSK1325760
Product Code: GSK1325760
INN or Proposed INN: AMBRISENTAN
Other descriptive name: ambrisentan
GlaxoSmithKline, S.A.NULLNot RecruitingFemale: yes
Male: yes
275United States;Spain;Austria;Russian Federation;Italy;United Kingdom;France;Czech Republic;Mexico;Canada;Argentina;Brazil;Netherlands;Germany;Japan;China;Korea, Republic of;Sweden
13EUCTR2012-001646-18-ES
(EUCTR)
25/04/201309/04/2013Study of a drug to treat chronic thromboembolic pulmonary hypertension (CTEPH)A randomised, multicentre, double-blind, placebo-controlled studyof ambrisentan in subjects with inoperable chronic thromboembolicpulmonary hypertension (CTEPH) Subjects with inoperable chronic thromboembolic pulmonary hypertension (CTEPH).
MedDRA version: 14.1;Level: LLT;Classification code 10068739;Term: Chronic thromboembolic pulmonary hypertension;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Trade Name: Volibris
Product Name: GSK1325760
Product Code: GSK1325760
INN or Proposed INN: Ambrisentan
Other descriptive name: ambrisentan
GlaxoSmithKline, S.A.NULLNot RecruitingFemale: yes
Male: yes
275United States;Spain;Austria;Russian Federation;Italy;United Kingdom;France;Czech Republic;Mexico;Canada;Argentina;Brazil;Netherlands;Germany;Japan;China;Korea, Republic of;Sweden